Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives

Table 6

Clinical trials with targeted therapies in patients with CCA.

Treatment	Patients with; biliary cancer	Well-diagnosed; CCA patients^a	Response rate; (%)	Median OS; (months)	References
Erlotinib		24 of 42	8	7.5	[105]
Lapatinib		9 of 17	0	5.2	[106]
Sorafenib		32 of 46	2.2	4.4	[101]
Sorafenib		19 de 31	0	9	[102]
Selumetinib		17 of 28	12	9.9	[104]
Sunitinib		41 of 56	8.9	4.8	[103]
Erlotinib + bevacizumab		43 of 53	12	9.9	[107]
GEMOX + cetuximab		27 of 30	63	11.6	[108]
GEMOX + bevacizumab		25 of 35	40	12.7	[109]
GEMOX + capecitabine + panitumumab		38 of 46	33	10	[110]
GEMOX vs	133	84	16	9.5	[111]
GEMOX + erlotinib	135	96	30	9.5	[111]
Gemcitabine + cisplatin + sorafenib		39	50	14.4	[112]

GEMOX: gemcitabine + oxaliplatin; OS: overall survival.
^aPatients with CCA (intrahepatic or extrahepatic) out of the total number of patients included as suffering from biliary tract cancer in the clinical trial.